17122-79-1Relevant academic research and scientific papers
Composition for Inhibiting or Treating for Acute Myeloid Leukemia or Metastatic Breast Cancer
-
Paragraph 0064-0072, (2021/05/11)
The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer comprising an indirubin derivative as an active ingredient. Use of the composition of the invention effectively inhibits the activity of FLT3 kinase. A composition for preventing or treating acute myeloid leukemia or metastatic breast cancer is provided.
PHARMACEUTICAL COMPOSITION FOR PREVENTING OR TREATING ACUTE MYELOID LEUKEMIA OR METASTATIC BREAST CANCER
-
Paragraph 0077-0080, (2020/09/09)
The present invention relates to a pharmaceutical composition for preventing or treating acute myeloid leukemia or metastatic breast cancer, comprising, as an active ingredient, an indirubin derivative. When the compound of the present invention is used,
The SARS coronavirus main protease having effects of inhibiting isatin - 5 - amide inhibitors
-
Paragraph 0049; 0050, (2017/04/19)
The invention provides an isatin-5-amide compound represented by a formula (1). The compound has an inhibition activity against SARS coronavirus main protease, and can be used as a SARS coronavirus main protease inhibiting agent, and can be applied in SAR
Isatin compounds as noncovalent SARS coronavirus 3C-like protease inhibitors
Zhou, Lu,Liu, Ying,Zhang, Weilin,Wei, Ping,Huang, Changkang,Pei, Jianfeng,Yuan, Yaxia,Lai, Luhua
, p. 3440 - 3443 (2007/10/03)
A series of isatin derivatives were synthesized and tested against SARS CoV 3C-like protease. Substitutions at the N-1 and C-5 positions were examined to elucidate the differences in substrate binding sites of the rhinovirus 3C protease and SARS CoV 3C-li
An improved synthesis of isonitrosoacetanilides
Rewcastle, Gordon W.,Sutherland, Hamish S.,Weir, Claudette A.,Blackburn, Adrian G.,Denny, William A.
, p. 8719 - 8721 (2007/10/03)
A novel two-step synthesis of isonitrosoacetanilides [2-(hydroxyimino)-N- phenylacetamides] has been developed, involving the initial acylation of aniline derivatives with 2,2-diacetoxyacetyl chloride, followed by reaction with hydroxylamine hydrochloride. The method works equally well with a variety of different aniline derivatives, including those with poor aqueous solubility and those containing electron rich ortho-substituents, neither of which react well under traditional conditions.
Biological activities and quantitative structure-activity relationships of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones as aldose reductase inhibitors
Yamagishi,Yamada,Ozaki,Asao,Shimizu,Suzuki,Matsumoto,Matsuoka,Matsumoto
, p. 2085 - 2094 (2007/10/02)
A series of spiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-triones were prepared and tested for aldose reductase inhibitory activity. The 6'- halogenated derivatives were found to be highly potent in vitro inhibitors of male rabbit lens aldose reductase and in vivo inhibitors of polyol accumulation in the sciatic nerves of galactosemic rats. Of these, (4R)-6'- chloro-3'-methylspiro[imidazolidine-4,4'(1'H)-quinazoline]-2,2',5(3'H)-trione (67) showed the most potent in vitro and in vivo activities. An oral dose of 3 g/kg of compound 67 caused neither death nor behavioral abnormality in the preliminary acute toxicity study using mice and rats. Compound 67 was selected as a candidate for further evaluation. The quantitative structure- activity relationships in this series are also discussed.
